db7
2 years ago
8k excerpt: "Convertible Loans Received
On December 9, 2021, AngioGenex, Inc., entered into definitive agreements with two unaffiliated accredited investors and the CEO and Chairman of the Board Michael Aronstein, executing convertible promissory notes fully due and payable on October 31, 2023 in an amount of $260,000 at 7% interest per annum. The Notes are convertible into unregistered securities, voluntarily by the Holders or automatically upon the completion of a financing of Fifteen Million Dollars or more. "
e-ore
3 years ago
Not sure what to make of the recent activity. They're 2 years delinquent in SEC filings. I liked them when they were "dark," suggested to me that they may have had investors willing to help with funding and wait until they were ahead enough to start filing. But then they filed the form 10, and nothing much happened. Maybe the plan now is to get revoked, flushing out the peon shareholders, then go start filing again in a couple of years. I'll be watching for filings. I did well with it, but haven't been a shareholder for a long time
e-ore
4 years ago
FOR IMMEDIATE RELEASE
February 10, 2020
ANGIOGENEX CO-DEVELOPING ANTI-CANCER DRUG
WITH WORLD RENOWNED CANCER CENTER
February 10, 2020 – AngioGenex, Inc. (AGGX.PK) (www.angiogenex.com) announced an exclusive agreement with Memorial Sloan Kettering Cancer Center (MSK) to license and advance a series of anti-ID compounds through the regulatory process and into human clinical trials. The company has secured exclusive, worldwide rights to the commercial development of pharmacological treatments based on these molecules. “We are delighted that after decades of basic and translational research aimed at hitting these targets, we will finally be able to determine their benefit to patients” said the Company’s Scientific Advisory Board Chairman and MSK Member Dr. Robert Benezra.
The scientific team, led by Dr. Benezra, has, in its recent in vitro and in vivo work identified a biological mechanism that allows certain fatal cancers of the liver, brain and breast to regenerate despite their apparent elimination by surgery, chemotherapy or radiation. Recent results indicate a fundamental mechanism, common to a significant group of cancers that allows these diseases to marshal a set of ID proteins which enable their persistent recurrence and lethality.
The anti-ID molecules that AngioGenex is developing include their lead drug AGXA, described in a recent Cell Reports paper (https://www.cell.com/cell-reports/pdf/S2211-1247(19)31128-3.pdf), and a new manuscript available online in BioRxiv (https://biorxiv.org/cgi/content/short/2020.01.06.894840v1). The drugs are intended to disrupt and ultimately disable the cellular pathways by which these intractable cancers repropagate.
The initial clinical trials will be designed to focus on certain cancers of the liver, which, at present, invariably recur and are most often fatal. MSK and AngioGenex contemplate working together to prepare and file an Investigational New Drug (IND) application with the FDA. The company expects to begin the formal process of obtaining FDA approval of its IND application during the first half of 2020. It is the company’s intention to have its IND accepted by the FDA and to begin a Phase 1 clinical trial at MSK within a year of that initial meeting.
Disclosures
Researchers at MSK, including Dr. Robert Benezra, have intellectual property interests associated with the anti-ID compounds. Dr. Robert Benezra is also a co-founder of, holds equity interests in, and serves on the board of directors and on the scientific advisory board of AngioGenex. MSK has financial interests in AngioGenex through an agreement to license intellectual property to the company.
About AngioGenex
AngioGenex, Inc. is a New York based biopharmaceutical research and development company focused on a particular biological pathway common to certain lethal cancers and age related macular degeneration. For additional information, please visit our website at www.angiogenex.com.
e-ore
6 years ago
AGGX .28 x .45 Website up after almost one and a half years of "under construction." Shareholder letter from June 2017:
"June 21, 2017
Dear AngioGenex Shareholder:
We would be remiss to begin this letter with anything but the very sad news of the passing
of our longtime Chairman, Dr. Richard Salvador. He was a major figure in the pharmaceutical
industry for decades that had both the vision to see the potential of our novel platform technology
and the perseverance to pursue its commercial development. Dick was as kind and thoughtful as he
was accomplished and committed. Those of us who had the pleasure to count him as a friend and
colleague will miss greatly this rare example of true humanity and personal integrity. We owe a
great debt to the man who led our Company as it succeeded in conceiving and developing the first
class of small molecule ID inhibitor drugs. As we pause to recognize Dr. Salvador’s great
contributions, I take this opportunity to bring you up to date on what we are doing to assure that his
hopes for our drug development plan are realized, as we move forward with renewed resolve and
resources.
As the discoverer of the ID mechanism and the scientific founder of AngioGenex, I have
done everything possible to support the company’s efforts within the parameters of its relationship
with Memorial Sloan Kettering Cancer Center, where I continue to run a lab focused on ID
research. About a year ago a very helpful change in leadership and policy at MSKCC, where I
remain a full member, afforded me the freedom to assume a more active role in the Company as
Chief Scientific and Interim Chief Executive Officer. That more entrepreneurial approach has
allowed us to recruit other important MSKCC scientists to join the AngioGenex team as well. These
include the world renowned oncologist Dr. Larry Norton (Head of the MSKCC Breast Cancer
Service) who has designed our human clinical trials, and medicinal chemist Dr. Ouathek Ouerfelli,
our head of pre-clinical R & D who has designed a series of second and third generation ID
Inhibitors, that have shown increased activity in models of Age Related Macular Degeneration, and
various forms of cancer.
Other important news on the Corporate, R&D and Intellectual Property fronts follow, but
perhaps of greatest interest to our shareholders in the fact that after a six year hiatus, AngioGenex,
Inc. has filed the necessary legal and financial disclosures with the Securities and Exchange
Commission to reclaim its status as a full reporting public company. As such our shares will soon
be eligible for trading on the NASDAQ Bulletin Board under the symbol AGGX.OB instead of on
the “Pink Sheets” as AGGX.PK. Subsequent increases in our market cap, capitalization, and share
price will allow us to apply for listing on the Small Cap and full NASDAQ exchanges, our ultimate
goal as a public company.
Our decision in 2010 to delist the company was motivated by our desire to prioritize our use
of capital on our research and drug development program, rather than incurring the expensive of
remaining a fully reporting public company. As a result we have made substantial progress
developing proprietary drugs that provide new hope for the treatment of ARMD and many forms of
cancer. Specific descriptions of these novel chemical entities (NCE’s) must wait a few weeks for
the completion and filing of additional patent applications.
The importance of our anti-angiogenic drugs on ocular disorders has been validated by a
world renowned leader in ARMD, Dr. Peter Campochiaro under a grant the Company made to the
Wilmer Eye Institute at Johns Hopkins Medical School. In his lab, in the accepted animal models
of ocular diseases, AngioGenex’s first generation lead drug candidate,AGX51 and its progeny have
proven to be effective at preventing the formation of blood vessels at a rate comparable to or
superior to the current standard of care, Regeneron’s highly profitable drug, Eylea.
Thanks in large part to our having created this proprietary armamentarium of ID-inhibitors,
we have confirmed the drugabilty of the ID target (long thought by many to be impossible), and
attracted a major new angel investor who has provided significant resources, and has committed to
financially support our effort going forward as an SEC reporting NASDAQ company.
Because of the manner in which we developed the drugs, AngioGenex owns the exclusive,
un-encumbered world-wide intellectual property rights to all of these new agents. This will allow us
to pursue future partnerships on more favorable terms if and when we chose to do so. To date a
number of ocular and oncology companies have opened dialogues about potential strategic
partnerships and/or acquisitions. We view these overtures as pre-mature but welcome the validation
of our work
As part of our re-boot we have engaged the top New York law firm of Davis Polk and
Wardwell, and the Eisner Amper LLP. accounting firm as our outside corporate counsel and
auditors respectively. We are also re-launching our web site at www.angiogenex.com to reflect all
of these changes and share the important progress we have made since we last communicated with
you. We all thank you for your continued support as we continue in our pursuit of creating a new
and impactful paradigm for the treatment of diseases of neo-vascularization.
Sincerely,
ROBERT BENEZRA PhD
Founder
Director, and
Chief Scientific and Executive Officer"
https://www.angiogenex.com/
e-ore
7 years ago
Looks like they want to do it themselves, or with a partner. From the filing
"Corporate Strategy – Clinical Development. Our team is poised to take this important medicine into the clinic for testing in both brain and breast cancer and in macular degeneration. Our current plan is to complete pre-clinical work for the filing of an Investigational New Drug Application (“IND”) in the ocular indication initially and conduct a Phase I/IIA clinical trial thereafter. If a partnership is obtained for eye disease drug development, those IND funds would be allocated to a cancer IND to be followed by Phase I/II clinical trials in patients with high risk of metastatic progression at MSKCC, under the supervision of Dr. Larry Norton, (Deputy Physician-in-Chief at MSKCC and Medical Director of the Evelyn H. Lauder Breast Center) the Head of the AngioGenex Scientific Advisory Board. With the initiation of these trials, designed to establish safety and proof of principle in humans, the Id story will have come full circle, from a basic biological finding in an academic lab to the discovery of an active chemical inhibitor to be tested on real patients in a clinic at the very institute where it all began. If we raise sufficient resources we would conduct both the oncology and ocular programs simultaneously.
The Path Forward. If we successfully complete safety and preliminary efficacy trials, we will seek further financing or a corporate partner for the completion of testing and the ultimate marketing of the drug. Our goal is to achieve interim milestones toward FDA approval in a number of disease indications with distinct proprietary pharmaceutical products."
e-ore
8 years ago
As usual with me it's about the "what ifs." Like what if big pharma is now involved? "Major changes" are different management setup and different website ownership/management. Increase in trading activity and price coincide with the dates of these developments. Not your typical OTC stock with a patent, Memorial Sloan Kettering a shareholder and their lead researcher also a director and shareholder.
https://www.mskcc.org/research-areas/labs/robert-benezra
Some info on their patent
New York City Based Biotech AngioGenex Inc. Reports on Recent Scientific Presentations and Publications
Source Press Release
Company AngioGenex
Tags Trial Results, Pre-clinical, Oncology
Date February 18, 2014
NEW YORK, February 18, 2014 -AngioGenex, Inc. (AGGX, PK) is a New York based biopharmaceutical company that discovers and develops novel and impactful drugs that target proteins (Id proteins) present in cancer but not healthy tissue. The Company's lead drug (Idantirx , AGX51 ) lowers the concentration of these proteins and causes a significant anti-cancer effect. The approval of the patent covering this drug, and the recent filings of additional patents covering new data on potentially broader use, allow the Company to share findings including the anti-cancer action of this remarkable molecule.
At the American Association of Cancer Research meeting in 2013, the Company reported on the ability of Idantirx to retard the growth and metastasis of implanted human breast cancer tumors in mice. Other experiments in cancer cells demonstrated that Idantirx ’s suppression of the Id proteins resulted in restoration of key anti-growth mediators and cell cycle control. Additional findings with Idantirx established the potential usefulness of the drug in combination with the widely prescribed chemotherapeutic drug, paclitaxel (Taxol ®). These studies were partially supported by an SBIR grant awarded by the National Cancer Institute to the Company in 2011 to expedite development of Idantirx .
In 2013, a chapter written by the AGX technical team appeared in the Annual Reports in Medicinal Chemistry. It reviewed the chemical and biological aspects of inhibiting protein-protein interaction and the new and unique procedures used in the discovery of Idantirx . “Targeting Protein–Protein Interactions to Treat Cancer—Recent Progress and Future Directions,” in Annual Reports in Medicinal Chemistry (Volume 48, 2013, Pages 227–245): sciencedirect.com.
The prestigious Nature Reviews Cancer published an article about the Id Proteins prepared by members of the AGX Cancer Scientific Advisory Board (SAB) in its February, 2014 issue.
Recently, Dr. Glenn Stoller a member of the AGX Ocular Scientific Advisory Board, reported significant advances in the Company's ocular program with Idantirx at the national Bascom-Palmer Symposium on Angiogenesis, Exudation, and Degeneration. Dr. Stoller provided experimental results showing that Idantirx is highly active in the animal model of human age-related macular degeneration that predicted the clinical success of Lucentis (Genentech ) and Eylea (Regeneron ).
Reflecting on the experimental results with Idantirx , Dr. Robert Benezra, the discoverer of the Id proteins and genes and head of the company's Scientific Advisory Board stated: "After almost a decade of research, we have an experimentally proven molecule with potent anti-Id activity, Idantirx . This drug has been shown to have potent anti-cancer action and is being tested for ocular use and other indications. The results with Idantirx confirm years of studies with mice lacking the Id genes and proteins." Dr. William Garland, CEO, added, "We have generated extensive data that establishes the ability of Idantirx to suppress key tumor promoting processes (growth, angiogenesis, cell migration) caused by the Id proteins. In these studies, Idantirx does not cause any apparent side effects probably because the Id proteins, the target of Idantirx , are very rarely found in healthy tissue.”
Register for streaming realtime charts, analysis tools, and prices.
Renee
1 year ago
protagonist12
7 years ago
Golf4Food
7 years ago
Hot Features
Premium
